Sana Biotechnology, Inc. (SANA) — Financial statements
Income statement, balance sheet, and cash flow for Sana Biotechnology, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cost of Revenue | 13 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Gross Profit | -13 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | ||||||
| R&D Expenses | 132↓36.8% | 209↓5.1% | 220↑9.4% | 201↓34.4% | 306 | |
| General & Administrative Expenses | 44↓30.8% | 64↓12.6% | 73↑2.4% | 72↑42.0% | 50 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 44↓30.8% | 64↓12.6% | 73↑2.4% | 72↑42.0% | 50 | |
| Other Expenses | 2 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 178↓34.7% | 273↓7.0% | 293↑7.5% | 273↓23.6% | 357 | |
| Total Costs & Expenses | 191↓30.0% | 273↓7.0% | 293↑7.5% | 273↓23.6% | 357 | |
| Operating Results | ||||||
| Operating Income | -191↑30.0% | -273↑7.0% | -293↓7.5% | -273↑23.6% | -357 | |
| Depreciation & Amortization | 13↓26.7% | 17↓29.2% | 25↑57.2% | 16↑41.1% | 11 | |
| EBITDA | -178↑30.2% | -255↑4.9% | -269↓4.5% | -257↑25.7% | -346 | |
| EBIT | -191↑30.0% | -273↑7.0% | -293↓7.5% | -273↑23.6% | -357 | |
| Interest & Other Income | ||||||
| Net Interest Income | 4↓63.3% | 10↑5.4% | 10↑164.2% | 4↑456.5% | 0.68 | |
| Interest Income | 4↓63.3% | 10↑5.4% | 10↑164.2% | 4↑456.5% | 0.68 | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Non-Operating Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Other Income / Expenses | -53↓992.2% | 6↓39.7% | 10↑220.1% | 3↑214.8% | 0.98 | |
| Income Before Tax | -244↑8.5% | -267↑5.8% | -283↓5.1% | -269↑24.3% | -356 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -244↑8.5% | -267↑5.8% | -283↓5.1% | -269↑24.3% | -356 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -244↑8.5% | -267↑5.8% | -283↓5.1% | -269↑24.3% | -356 | |
| Bottom-Line Net Income | -244↑8.5% | -267↑5.8% | -283↓5.1% | -269↑24.3% | -356 | |
| EPS (Basic) | -0.96↑17.2% | -1.16↑20.5% | -1.46↓2.1% | -1.43↑33.2% | -2.14 | |
| EPS (Diluted) | -0.96↑17.2% | -1.16↑20.5% | -1.46↓2.1% | -1.43↑33.2% | -2.14 | |
| Weighted Average Shares | 253↑9.7% | 231↑18.7% | 195↑3.3% | 188↑13.2% | 166 | |
| Weighted Average Diluted Shares | 253↑9.7% | 231↑18.7% | 195↑3.3% | 188↑13.2% | 166 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.